[ad_1]
CAMBRIDGE, Massachusetts – (BUSINESS WIRE) – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapies and vaccines, confirmed today that the company has signed a supply agreement with the government of the Republic of Korea to provide 40 Millions of doses of Modern COVID-19 Vaccine to support the government’s goal of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, deliveries would begin in May 2021. The Modern COVID-19 vaccine is not currently approved for use in South Korea, and the Company will work with regulators to obtain the necessary approvals prior to distribution.
“We thank the Republic of Korea for partnering with us to bring the Modern COVID-19 vaccine to South Korea. The government has moved very quickly to do this in the face of the pandemic. We believe this supply agreement is an important step towards building a lasting future collaboration between Moderna and the Republic of Korea, ”said Stéphane Bancel, Moderna’s CEO. “We look forward to continuing discussions with government officials and building a stronger Moderna scientific and clinical presence in South Korea.”
About Moderna
Moderna is advancing the science of messenger RNA (mRNA) to create a new class of transformative drugs for patients. MRNA drugs are designed to direct the cells of the body to produce intracellular, membrane or secreted proteins that may have a therapeutic or preventive benefit and have the potential to address a wide spectrum of diseases. The company’s platform is built on continuous advancements in basic and applied mRNA science, delivery technology, and manufacturing, giving Moderna the ability to pursue a strong portfolio of new candidates for development in parallel. Moderna is developing therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune and inflammatory diseases, independently and with strategic partners.
Modern, based in Cambridge, Mass., Currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the Department Defense Department and BARDA. Moderna has been named one of the top biopharmaceutical companies by Sciences for the past six years. For more information, visit www.modernatx.com.
Authorized use
The Modern COVID-19 vaccine has not been approved or licensed by the United States Food and Drug Administration (FDA), but the FDA has licensed the vaccine for emergency use in people 18 years of age or older.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including: the Company’s development of a novel coronavirus vaccine and the possible provision of the Vaccine. Modern COVID-19 for the government of South Korea. In some cases, forward-looking statements may be identified by terminology such as “will”, “may”, “should”, “may”, “expects”, “intends”, “plans”, “aims”, “anticipates,” “” Believe ”,“ estimate ”,“ predict ”,“ potential ”,“ continue ”or the negatives of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are not promises or guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control. and what could cause actual results to differ materially from those expressed or implied in these forward-looking statements. These risks, uncertainties and other factors include, but are not limited to: the fact that there has never been a commercial product using mRNA technology approved for use; the fact that the rapid response technology used by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of Modern COVID-19 vaccine observed to date may change adversely in ongoing analyzes of trial data or post-marketing; Despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or other regulatory agencies may not agree with the Company’s regulatory approval strategies, the components of our submissions, such as clinical trial designs, conduct and the methodologies, or the sufficiency of the data presented. ; Moderna may encounter delays in meeting manufacturing or supply deadlines or disruptions in its Moderna COVID-19 vaccine distribution plans; if, and when, any application for a biological license and / or application for an emergency use authorization can be submitted and finally approved by the regulatory authorities; Potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, clinical and manufacturing trials, supply chain disruptions, adverse effects on health systems, and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the US Securities and Exchange Commission (SEC) and in subsequent filings made. by Moderna before the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility to update or revise the forward-looking statements contained in this press release in the event of new information, future developments, or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.
